Pure Global AI
NCT06388187Not yet recruiting

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity
Novo Nordisk A/SPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
Cagrilintide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Novo Nordisk A/S
Location
Costa Mesa,Plantation,Indianapolis,Wilmington,Dallas,Arlington,Olympia,Surrey,Halifax,Hamilton,Pierre-Benite,Saint Herblain,Toulouse Cedex 9,Essen,Hamburg,Leipzig,Münster,Witten,Bradford-on-Avon,Brist, Canada,France,Germany,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Jun 24, 2024
End date
Apr 10, 2026
Enrollment
300 participants
Primary outcome

Relative change in body weight,Achievement of ≥5% weight reduction

Summary

This study will look at how well CagriSema helps people with excess body weight lose weight.
 CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and
 semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will
 either get CagriSema or dummy medicine and which treatment participant get is decided by
 chance. The study will last for about 1½ years for each participant.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06388187
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06388187 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.